Comparative Pharmacology
Head-to-head clinical analysis: LYNOZYFIC versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYNOZYFIC versus NYSTAFORM.
LYNOZYFIC vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin transporter (SERT) in the presynaptic terminal, increasing synaptic serotonin levels.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
1000 mg intravenously every 12 hours infused over 2 hours
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Terminal elimination half-life is 12.4 hours (range 11.2–14.1 hours) in patients with normal renal function; allows twice-daily dosing for steady-state within 3 days.
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion accounts for 25%; the remaining 10% is metabolized by hepatic CYP3A4-mediated oxidation.
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category C
Category C
Antifungal
Antifungal